It expects revenues to be in the order of £31.5mln in the first half of its financial year, which equates to a 12% rise at constant currencies.
This solid performance was supported by acquisition of Alerpharma last June.
Chief executive Manuel Llobet told investors: “Overall we are executing our business strategy and, in addition to growing our European business, remain focused on executing a pivotal clinical trial programme, potentially paving the way towards the US and expanding into new market segments with a strong new product pipeline.
“Our business is now in a very strong position to generate continuing growth over the coming years."
The company has developed a suite of treatments aimed at common pollen allergies that have created a very sound business in Europe.
Analysts reckon a long-term opportunity will come in the States where the company’s flagship product, Pollinex Quattro, is set to hit the market in the next three to four years.